271 related articles for article (PubMed ID: 35890254)
1. Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates.
Seong J; Kim K
Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890254
[TBL] [Abstract][Full Text] [Related]
2.
Seong J; Jeong S; Kim S; Yun S; Baek Y; Kim K
Biomater Sci; 2023 Jun; 11(13):4537-4548. PubMed ID: 37158297
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells.
Zhao L; Niu C; Shi X; Xu D; Li M; Cui J; Li W; Xu J; Jin H
Oncol Lett; 2018 Jul; 16(1):1180-1188. PubMed ID: 30061941
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Antitumor Immunity Using a Tumor Cell Lysate-Encapsulated CO
Won JE; Byeon Y; Wi TI; Lee JM; Kang TH; Lee JW; Shin BC; Han HD; Park YM
ACS Appl Bio Mater; 2019 Jun; 2(6):2481-2489. PubMed ID: 35030704
[TBL] [Abstract][Full Text] [Related]
5. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy.
Hatfield P; Merrick AE; West E; O'Donnell D; Selby P; Vile R; Melcher AA
J Immunother; 2008 Sep; 31(7):620-32. PubMed ID: 18600182
[TBL] [Abstract][Full Text] [Related]
6. Comparison of four methods of colon cancer cell lysates preparation for
Roufarshbaf M; Esmaeil N; Akbari V
Res Pharm Sci; 2022 Feb; 17(1):43-52. PubMed ID: 34909043
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine.
Shi GN; Hu M; Chen C; Fu J; Shao S; Zhou Y; Wu L; Zhang T
Ther Adv Med Oncol; 2021; 13():1758835920987056. PubMed ID: 33613696
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
9. Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.
Montico B; Lapenta C; Ravo M; Martorelli D; Muraro E; Zeng B; Comaro E; Spada M; Donati S; Santini SM; Tarallo R; Giurato G; Rizzo F; Weisz A; Belardelli F; Dolcetti R; Dal Col J
Oncoimmunology; 2017; 6(11):e1356964. PubMed ID: 29147614
[TBL] [Abstract][Full Text] [Related]
10. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
11. Uplifting Antitumor Immunotherapy with Lymph-Node-Targeted and Ratio-Controlled Codelivery of Tumor Cell Lysate and Adjuvant.
Cui G; Sun Y; Qu L; Shen C; Sun Y; Meng F; Zheng Y; Zhong Z
Adv Healthc Mater; 2024 Mar; ():e2303690. PubMed ID: 38458152
[TBL] [Abstract][Full Text] [Related]
12. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
13. Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines.
Wen CC; Chen HM; Chen SS; Huang LT; Chang WT; Wei WC; Chou LC; Arulselvan P; Wu JB; Kuo SC; Yang NS
J Biomed Sci; 2011 Jun; 18(1):44. PubMed ID: 21689407
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell lysates as immunogenic sources for cancer vaccine design.
González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
[TBL] [Abstract][Full Text] [Related]
15. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells.
Moehler MH; Zeidler M; Wilsberg V; Cornelis JJ; Woelfel T; Rommelaere J; Galle PR; Heike M
Hum Gene Ther; 2005 Aug; 16(8):996-1005. PubMed ID: 16076257
[TBL] [Abstract][Full Text] [Related]
16. Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction.
Dong B; Ding Y; Huang Q; Guan X
Med Sci Monit; 2019 Jan; 25():500-515. PubMed ID: 30653481
[TBL] [Abstract][Full Text] [Related]
17. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
Salem ML
Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
[TBL] [Abstract][Full Text] [Related]
18. Tumor Cell-associated Exosomes Robustly Elicit Anti-tumor Immune Responses through Modulating Dendritic Cell Vaccines in Lung Tumor.
Wang C; Huang X; Wu Y; Wang J; Li F; Guo G
Int J Biol Sci; 2020; 16(4):633-643. PubMed ID: 32025211
[TBL] [Abstract][Full Text] [Related]
19. [Antitumor effects and mechanisms of a dendritic cell vaccine which silenced SOCS1 by siRNA, stimulated by OK-432 and pulsed with lysate of HepG2 cells].
Song HF; Zhou J; Pan K; Wang QJ; Wang H; Huang LX; Li YQ; Xia JC
Ai Zheng; 2008 Jul; 27(7):685-91. PubMed ID: 18606059
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study.
El-Ashmawy NE; El-Zamarany EA; Khedr EG; El-Bahrawy HA; El-Feky OA
Clin Exp Med; 2018 Nov; 18(4):535-546. PubMed ID: 30062618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
